查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1513872

循环性肿瘤细胞(CTC) 诊断的全球市场

Circulating Tumor Cell (CTC) Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球循环性肿瘤细胞(CTC) 诊断市场预计将达到 238 亿美元

循环性肿瘤细胞(CTC) 诊断的全球市场预计到 2023 年将达到 114 亿美元，预计在 2023 年至 2030 年分析期间将以 11.2% 的复合年增长率增长，并在 2030 年达到 238 亿美元。检测与富集技术是本报告分析的细分市场之一，预计复合年增长率为 10.8%，到分析期结束时将达到 154 亿美元。分析期间，分析技术领域的复合年增长率预计为 12.7%。

美国市场预估30亿美元，中国预估年复合成长率10.2%

到 2023 年，美国循环性肿瘤细胞(CTC) 诊断市场预计将达到 30 亿美元。中国作为全球第二大经济体，预计2030年市场规模将达36亿美元，2023-2030年分析期间复合年增长率为10.2%。其他值得注意的区域市场包括日本和加拿大，预计在分析期间复合年增长率分别为 10.0% 和 9.4%。在欧洲，德国预计复合年增长率为 7.8%。

全球循环性肿瘤细胞(CTC) 诊断市场 - 主要趋势与驱动因素总结

循环性肿瘤细胞(CTC) 在推进癌症诊断和管理、指导治疗策略的製定以及提供关键见解以帮助监测转移和復发方面已变得至关重要。作为液态切片创新方法的一部分，CTC 诊断可无创地评估癌症进展和治疗效果，促进肿瘤復发的早期检测。这种方法利用多种技术，包括生物标记介导的平台和先进的生化技术，从临床血液样本中分离和分析 CTC。然而，这些技术常常与癌细胞异质性作斗争，对检测灵敏度提出了挑战。儘管有这些挑战，CTC 计数和分子分析可以显着预测癌症预后，这提出了将敏感的 CTC 检测技术纳入常规临床管理以改善患者预后的重要性。

最近的技术进展引入了更灵敏且独立于生物标记的方法来分离 CTC，从而提高了癌症预后的准确性和敏感性。一个值得注意的进展是使用表面带电的超顺磁性奈米探针，它利用了与瓦伯格效应相关的生物电现象，其中癌细胞由于葡萄糖摄取和乳酸分泌增加而表现出明显的负电荷。此方法与依赖亲和性和反应的传统技术相反，可能无法捕捉 CTC 的所有亚群，特别是那些经历上皮间质转化 (EMT) 的亚群。这些先进的方法，包括基于密度的分离和微流体装置，提高了 CTC 捕获的特异性和效率，使其在准确性和可靠性至关重要的临床环境中发挥重要作用。

CTC 诊断的使用日益增长，因为它融入了更广泛的精准医学范例，该范例根据透过 CTC 分析确定的个别患者特征量身定制医疗保健治疗。随着全球癌症发生率的上升，迫切需要CTC诊断等创新诊断方法。 CTC 诊断可以为患者提供侵入性较小的选择，并促进转移的早期检测和疾病进展的监测，从而对癌症管理产生重大影响。 CTC 技术开发中的跨学科合作、计算生物学的进步、资金筹措的增加以及医疗保健政策支援正在进一步推动此类先进诊断工具的采用。随着CTC诊断越来越融入临床实践，预计癌症治疗的模式将发生巨大变化，从而带来更个人化、有效且及时的治疗策略。

受访企业范例（共48家）

  • ApoCell, Inc.
  • Biocep Ltd.
  • Biocept, Inc.
  • Biofluidica Microtechnologies LLC
  • Celltraffix Inc.
  • Clearbridge Biomedics
  • Creatv Microtech, Inc.
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • IVDiagnostics, Inc.
  • Janssen Diagnostics LLC
  • QIAGEN Hannover GmbH
  • Rarecells Sas
  • Screencell
  • Stemcell Technologies, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 世界其他地区

第四章 比赛

简介目录
Product Code: MCP-7869

Global Circulating Tumor Cell (CTC) Diagnostics Market to Reach US$23.8 Billion by 2030

The global market for Circulating Tumor Cell (CTC) Diagnostics estimated at US$11.4 Billion in the year 2023, is expected to reach US$23.8 Billion by 2030, growing at a CAGR of 11.2% over the analysis period 2023-2030. Detection & EnrichmentTechnology, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$15.4 Billion by the end of the analysis period. Growth in the Analysis Technology segment is estimated at 12.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 10.2% CAGR

The Circulating Tumor Cell (CTC) Diagnostics market in the U.S. is estimated at US$3.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.0% and 9.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Global Circulating Tumor Cell (CTC) Diagnostics Market - Key Trends and Drivers Summarized

Circulating tumor cells (CTCs) have become crucial in advancing cancer diagnosis and management, providing key insights that guide the development of treatment strategies and help monitor metastasis and recurrence. As part of an innovative approach known as liquid biopsy, CTC diagnostics allow for the non-invasive evaluation of cancer progression and treatment effectiveness, facilitating the early detection of tumor recurrence. This approach leverages various technologies, including biomarker-mediated platforms and advanced biochemical methods, to isolate and analyze CTCs from clinical blood samples. These technologies, however, often struggle with the heterogeneity of tumor cells, which can lead to challenges in detection sensitivity. Despite these challenges, the enumeration and molecular profiling of CTCs can significantly predict cancer prognosis, underscoring the importance of integrating sensitive CTC detection technologies into routine clinical management to enhance patient outcomes.

Recent technological advancements have introduced more sensitive, biomarker-independent methods for isolating CTCs, enhancing the accuracy and sensitivity of cancer prognosis. A notable development is the use of surface-charged superparamagnetic nanoprobes, which capitalize on the bio-electrical phenomena associated with the Warburg effect, where cancer cells exhibit a distinct negative charge due to elevated glucose uptake and lactic acid secretion. This method contrasts with traditional techniques that rely on immuno-affinity reactions and can miss capturing all subpopulations of CTCs, particularly those undergoing epithelial-to-mesenchymal transition (EMT). These advanced approaches, including density-based separation and microfluidic devices, improve the specificity and efficiency of CTC capture, making them invaluable in clinical settings where precision and reliability are paramount.

The growing utilization of CTC diagnostics is driven by their integration into the broader paradigm of precision medicine, which tailors healthcare treatments to individual patient characteristics identified through CTC analysis. With the global rise in cancer incidence, there is a pressing need for innovative diagnostic methods like CTC diagnostics, which offer less invasive options for patients and can significantly impact cancer management by facilitating the early detection of metastasis and monitoring disease progression. Interdisciplinary collaboration in the development of CTC technologies, advancements in computational biology, increased funding, and supportive healthcare policies are further catalyzing the adoption of these advanced diagnostic tools. As CTC diagnostics become more integrated into clinical practice, they promise to transform the landscape of cancer treatment, leading to more personalized, effective, and timely therapeutic strategies.

Select Competitors (Total 48 Featured) -

  • ApoCell, Inc.
  • Biocep Ltd.
  • Biocept, Inc.
  • Biofluidica Microtechnologies LLC
  • Celltraffix Inc.
  • Clearbridge Biomedics
  • Creatv Microtech, Inc.
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • IVDiagnostics, Inc.
  • Janssen Diagnostics LLC
  • QIAGEN Hannover GmbH
  • Rarecells Sas
  • Screencell
  • Stemcell Technologies, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Circulating Tumor Cell (CTC) Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Cancer Worldwide: Propels Growth in Circulating Tumor Cell (CTC) Diagnostics as a Vital Tool for Early Detection and Monitoring
    • Technological Advancements in CTC Isolation and Analysis Techniques: Drives Adoption of High-Performance Diagnostic Platforms
    • Rising Demand for Personalized Medicine: Throws the Spotlight On CTC Diagnostics for Tailored Treatment Strategies
    • Regulatory Shifts Towards Companion Diagnostics: Strengthens Business Case for CTC Testing in Treatment Decision-making
    • Growing Focus on Liquid Biopsy as a Non-invasive Diagnostic Tool: Expands Addressable Market Opportunity for CTC Testing
    • Growing Focus on Liquid Biopsy as a Non-invasive Diagnostic Tool: Expands Addressable Market Opportunity for CTC Testing
    • Emerging Applications of CTCs in Cancer Prognosis and Treatment Monitoring: Accelerates Demand for Comprehensive Diagnostic Solutions
    • Increasing Investments in Precision Oncology Research: Drives Adoption of CTC Technologies in Biomarker Discovery and Drug Development
    • Expansion of Point-of-Care Testing Capabilities: Propels Market Growth by Offering Rapid and Convenient CTC Analysis Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Circulating Tumor Cell (CTC) Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Detection & Enrichment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Detection & Enrichment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Detection & Enrichment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Direct Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Direct Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Direct Detection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Body Fluids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Body Fluids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Body Fluids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Clinical / Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Clinical / Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Clinical / Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • JAPAN
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • CHINA
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • EUROPE
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • FRANCE
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • GERMANY
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Asia-Pacific 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of World 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030

IV. COMPETITION